Review of Limited Systemic Absorption of Orlistat, a Lipase Inhibitor, in Healthy Human Volunteers

  title={Review of Limited Systemic Absorption of Orlistat, a Lipase Inhibitor, in Healthy Human Volunteers},
  author={J. Zhi and A. T. Melia and H. Eggers and R. Joly and I. Patel},
  journal={The Journal of Clinical Pharmacology},
Orlistat, a lipase inhibitor, acts locally in the gastrointestinal tract. Systemic absorption is not required for its efficacy, but knowledge of the extent of its systemic absorption is important for its safe use in obese patients, the intended target population. Pharmacokinetic screening was carried out by monitoring plasma concentrations of unchanged orlistat in 25 phase 1 studies (including two mass balance studies) in normal and obese healthy volunteers. The results of these studies… Expand
139 Citations
Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers.
  • 138
  • PDF
Metabolic Profiles of Minimally Absorbed Orlistat in Obese/Overweight Volunteers
  • 76
Orlistat: a review of its use in the management of obesity.
  • 84
  • Highly Influenced
Orlistat — A Novel Weight Loss Therapy
  • 66
Pharmacodynamic testing and new validated HPLC method to assess the interchangeability between multi-source orlistat capsules
  • PDF


Lipase inhibition: a novel concept in the treatment of obesity.
  • M. Drent, E. A. van der Veen
  • Medicine
  • International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
  • 1993
  • 154
Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin).
  • 153
JHG: Comparison of galenic formulations of orlistat (tetrahydrolipstatin): a pharmacological approach
  • Drug Invest
  • 1993